TY - JOUR
T1 - Unbiasing costs? An appraisal of economic assessment alongside randomized trials in neonatology
AU - Hay, Susanne
AU - Mowitz, Meredith
AU - Dukhovny, Dmitry
AU - Viner, Christine
AU - Levin, Jonathan
AU - King, Brian
AU - Zupancic, John A.F.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Economic evaluations performed alongside randomized controlled trials benefit from the protections against bias inherent in randomization. In this systematic review, we assessed the frequency and quality of economic assessments alongside randomized controlled trials of interventions in neonates published between 1990 and 2016. Over that period, 58 economic assessments were published, corresponding to approximately 2% of RCTs. We noted significant methodological limitations of these studies, including limitation of included costs to the health sector or payer rather than broader categories such as family or community expenditures (81%), short time horizon for cost measurement (less than one year in 60%), lack of reporting of uncertainty (26%), and infrequent analysis of costs and effects in a single metric (combined in 45%). Strategies for improving the quality and frequency of economic evaluations in neonatology are discussed, including selection of appropriate trials, funding, and peer review.
AB - Economic evaluations performed alongside randomized controlled trials benefit from the protections against bias inherent in randomization. In this systematic review, we assessed the frequency and quality of economic assessments alongside randomized controlled trials of interventions in neonates published between 1990 and 2016. Over that period, 58 economic assessments were published, corresponding to approximately 2% of RCTs. We noted significant methodological limitations of these studies, including limitation of included costs to the health sector or payer rather than broader categories such as family or community expenditures (81%), short time horizon for cost measurement (less than one year in 60%), lack of reporting of uncertainty (26%), and infrequent analysis of costs and effects in a single metric (combined in 45%). Strategies for improving the quality and frequency of economic evaluations in neonatology are discussed, including selection of appropriate trials, funding, and peer review.
KW - Controlled clinical trials
KW - Costs and cost analysis
KW - Infant
KW - Newborn
UR - http://www.scopus.com/inward/record.url?scp=85101046342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101046342&partnerID=8YFLogxK
U2 - 10.1016/j.semperi.2021.151391
DO - 10.1016/j.semperi.2021.151391
M3 - Article
C2 - 33583609
AN - SCOPUS:85101046342
SN - 0146-0005
VL - 45
JO - Seminars in Perinatology
JF - Seminars in Perinatology
IS - 3
M1 - 151391
ER -